Invesco Ltd. Outlook Therapeutics, Inc. Transaction History

Invesco Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.22 - $0.66 $2,274 - $6,823	-10,338 Reduced 20.47%	40,175 $15,000
Q2 2023 Aug 11, 2023	BUY	$1.02 - $1.89 $3,051 - $5,654	2,992 Added 6.3%	50,513 $87,000
Q1 2023 May 12, 2023	BUY	$1.0 - $1.35 $7,872 - $10,627	7,872 Added 19.85%	47,521 $51,000
Q4 2022 Feb 13, 2023	SELL	$0.87 - $1.33 $4,409 - $6,740	-5,068 Reduced 11.33%	39,649 $42,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $6,291 - $7,771	6,168 Added 16.0%	44,717 $55,000
Q2 2022 Aug 15, 2022	BUY	$0.91 - $2.01 $7,286 - $16,094	8,007 Added 26.22%	38,549 $39,000
Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $231 - $385	-190 Reduced 0.62%	30,542 $54,000
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.23 $762 - $1,338	-600 Reduced 1.91%	30,732 $42,000
Q3 2021 Nov 15, 2021	BUY	$2.12 - $2.76 $16,697 - $21,737	7,876 Added 33.58%	31,332 $68,000
Q2 2021 Aug 17, 2021	BUY	$1.78 - $2.76 $41,751 - $64,738	23,456 New	23,456 $58,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.